Tenderwize
Retour à la recherche

Open-house biologics rebate agreement for Natalizumab (subcutaneous formulation)

Techniker Krankenkasse·Hamburg, Germany·Deadline Jan 30, 2028 · 522 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-36 - Natalizumab (Darreichungsform zur subkutanen Injektion)

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...

Participation is limited to pharmaceutical undertakings for the relevant medicinal product and requires valid authorisa...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Conclusion of pharmaceutical rebate agreements for Natalizumab (subcutaneous injection formulation).
  • Open-house arrangement with uniform contractual conditions and no individual negotiations.
Afficher le résumé complet

Open-house pharmaceutical supply arrangement for Natalizumab (subcutaneous formulation) in Germany, led by Techniker Krankenkasse with HEK and hkk as participating buyers. The notice states that any suitable pharmaceutical undertaking may join during the contract period, with no exclusivity and no individual negotiations. The contract runs for up to 24 months from 01.02.2026 and ends no later than 31.01.2028. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the documents are only available electronically. No contract value is stated.

Risques

Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...

Participation is limited to pharmaceutical undertakings for the relevant medicinal product and requires valid authorisa...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal product(s).
  • Applicant must have its seat in Germany, another EU Member State, or another EEA State.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-house biologics rebate agreement for Natalizumab (subcutaneous formulation)

Single lot covering the conclusion of pharmaceutical rebate agreements under Section 130a(8) SGB V for Natalizumab in subcutaneous formulation. Scope is nationwide in Germany. The notice says the arrangement is open-house, with uniform terms, no exclusivity, and no individual negotiations. Lot information is taken from structured data and the notice text.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jan 2026 - Jan 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Jan 30, 2028

Détails de la procédure

Date de publication
23 Nov 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
776899-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3